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disease (CKD) has drawn great attention. In the case of
progressive renal disease, decline in renal function corre-
lates with the extent of interstitial fibrosis, irrespective of
the initiating pathology. From a histological perspective,
the disease is characterized by myofibroblast accumula-
tion, extracellular matrix (ECM) deposition, inflammation,
tubular atrophy, and microvascular rarefaction. The
complex intertexture between cellular elements and
molecular mediators in tissue damage may be initially
adaptive, leading to functional and architectural regener-
ation; with chronic stimuli turning out to be maladaptive,
resulting in permanent scar formation and irreversible
organ failure. Scar-producing myofibroblasts or activated
fibroblasts, characterized by the expression of cytoskeletal
protein a-smooth muscle actin and contractile function,
deposit collagenous ECM and play a crucial role in fibrotic
diseases. In animal models of progressive renal disease, loss
of the microvasculature integrity also correlates with the
degree of glomerulosclerosis and tubulointerstitial fibrosis.
Persistent or repeated injuries lead to peritubular capillary
rarefaction, chronic hypoxia, tubular cell loss, cytokine
release, inflammatory cell recruitment, pericyte* Corresponding author. Graduate Institute of Physiology, College
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http://dx.doi.org/10.1016/j.jfma.2012.07.028proliferation, and myofibroblast differentiation.1e5 Peri-
cyteemyofibroblast transition and ECM deposition further
aggravate tissue hypoxia, glomerular and tubulointerstitial
injuries, forming a vicious cycle.
Investigating the origin of myofibroblasts has been the
cardinal issue of fibrogenesis research for the past 20 years.
The process of transition from epithelial to mesenchymal
cells postulated that tubule epithelial cells (under chronic
injury) acquire mesenchymal phenotype, traverse the
basement membrane, and transform into interstitial myo-
fibroblasts. Using both kinetic mathematical modeling and
state-of-the-art genetic fate mapping techniques in vivo,
recent identification of microvascular pericytes as the
major source of myofibroblasts readjusts our viewpoint
from epithelial injury to microvasculature.2,3 The fact that
pericytes are a major source of myofibroblasts serves to
readjust the focus of fibrosis research to the vasculature. In
unilateral ureteral obstruction (UUO), an animal model of
progressive renal fibrosis, obstructed kidney results in
downregulation of renal blood flow and glomerular filtra-
tion rate, suggesting that circulating factors may be
important triggers eliciting pericytes response. Pericytes
have been reported to serve as paracrine cells supporting
vascular integrity, providing important angiogenic factors
including vascular endothelial growth factor (VEGF) and
angiopoietin-1 (Ang-1).6 By contrast, endothelial cells are
the source of platelet-derived growth factor (PDGF),
transforming growth factor-b1, and fibroblast growth
factor-2, all of which are important growth factors for& Formosan Medical Association. All rights reserved.
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relay injured signals from obstructed tubules or altered
hemodynamic status to stimulate adjoining pericytes.
Consequently, the pathobiological crosstalk between
endothelial cells and pericytes in progressive renal fibrosis
should be further delineated. Our recent study proved that
either blocking VEGF receptor signaling on the endothelial
cells or PDGF receptor signaling on the pericytes prevent
pericyte differentiation, proliferation, and attenuate renal
fibrosis.1,7 VEGF receptor-2 blockade also decreases the
recruitment of inflammatory cells.1 Focusing renal fibrosis
on microvascular rarefaction takes our notion to a new field
of vision.
Ang-1 and Ang-2 are ligands of the Tie-2 receptor,
a second class of vascular-specific receptor tyrosine
kinases. The Ang/Tie-2 system tightly controls the endo-
thelial phenotype during angiogenesis in a unique and
nonredundant fashion. Ang-1-mediated Tie-2 activation is
required to maintain the quiescent resting endothelium.
While Ang-1 functions are antagonized by Ang-2, Ang-2
behaves in a context-dependent manner. Ang-2 destabilizes
the quiescent endothelium and primes it to respond to
exogenous stimuli, thereby modulating the activities of
inflammatory (tumor necrosis factor-a and interleukin-1)
and angiogenic (VEGF) cytokines. In coupling with VEGF,
Ang-2 is an important angiogenic stimulus of destabilized
vessels. When VEGF signaling is inhibited or absent, Ang-2
leads to cell apoptosis and vascular regression. VEGF may
further regulate Ang/Tie-2 signaling by inducing proteolytic
cleavage and shedding of Tie-2 through a phosphatidylino-
sitol 3-kinase/Akt-dependent pathway; therefore, VEGF
may inhibit vascular stabilization in an Ang-dependent
manner. Moreover, studies by Rao et al. pointed out that
pericytes and macrophages should cooperate in develop-
mentally scheduled vascular regression.8 In response to the
Wnt7b ligand from macrophages, vascular endothelial cells
enter the cell cycle and in the absence of survival signal,
blocked by Ang-2 from pericytes, they undergo cell cycle-
dependent apoptosis. Noteworthily, we demonstrated
that Wn7b ligand is produced by injured kidney macro-
phages.9 During renal fibrosis, analyzing whether Ang-2
released by expanded myofibroblasts along with Wnt7b
from inflammatory macrophage, leading to peritubular
capillary loss and the consequent chronic ischemia will be
of great interest.
Based on the specific features, Ang-2 comes into our
notice. Ang/Tie-2 system is a delicate growth factor family
with directly opposing effects, constitutively expressed
Ang-1 which is negatively regulated by Ang-2. In embryo-
logic research, Ang-2 overexpression displays severer
phenotype than Ang-1 knock-out. The context-dependent
action of Ang-2 makes it more vulnerable to be aimed at,
with minimal adverse outcome. Elevated levels of plasma
Ang-2 have been reported in CKD and end-stage renal
disease, which correlates with that observed in cardiovas-
cular disease; and most important of all, such high levels
predict the long-term mortality in patients with CKD.10
Even with the help of elaborative statistical analyses,observation clinical study can only demonstrate the corre-
lation, but not the causality. Several issues should be
addressed and get straightened out via the animal model.
First of all, the source of increased circulating Ang-2 levels
should be investigated. We can use either remnant kidney
model to study the stimulatory effect of uremic milieu, or
UUO model merely centered on the fibrotic kidney itself.
Because Ang-2 serves as the link between angiogenic and
inflammatory pathway, Ang-2 signaling between diverse
cellular elements in renal fibrosis including endothelial
cells, pericytes, myofibroblasts, and macrophages should
be described. Considering the detrimental effect of Ang-2
in progressive renal disease, the ultimate goal is to estab-
lish the beneficial outcome by targeting Ang-2.Acknowledgments
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